Details of the Drug Combinations

General Information of This Drug (ID: DMZQOUX)

Drug Name

Trastuzumab DMZQOUX

Synonyms

Herceptin; Herceptin (TN); Trastuzumab (INN); Trastuzumab (genetical recombination); Trastuzumab (genetical recombination) (JAN); Trastuzumab (ERBB2 mAb inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Inflammatory breast cancer	2C62	Approved	[2]
Lung cancer	2C25.0	Approved	[3]
Gastric adenocarcinoma	2B72	Application submitted	[4]
HER2-positive breast cancer	2C60-2C65	Application submitted	[4]
Gastric cancer	2B72	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Antibody

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bevacizumab + Trastuzumab	DCEL30Y	Bevacizumab	Breast cancer	[6]
Pertuzumab + Trastuzumab	DC8DT7B	Pertuzumab	Breast cancer	[4]
------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
2	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32.
3	Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec;600(7890):727-730.
6	ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer